Sprint Bioscience AB (OSTO:SPRINT) Piotroski F-Score: 7 (As of Jul. 03, 2026) — 133% Above Median


OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr4.06
GF Value kr2.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sprint Bioscience AB Piotroski F-Score?

Sprint Bioscience AB OSTO:SPRINT -4.92% 32 Piotroski F-Score is 7 as of Jul. 03, 2026, which is 133% above its 10-year median of 3.00. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,336 Biotechnology companies, Sprint Bioscience AB ranks better than 96.93% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sprint Bioscience AB has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Sprint Bioscience AB's Piotroski F-Score or its related term are showing as below:

OSTO:SPRINT' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Sprint Bioscience AB was 8. The lowest was 1. And the median was 3.

Sprint Bioscience AB  (OSTO:SPRINT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sprint Bioscience AB Piotroski F-Score Related Terms


Sprint Bioscience AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Piotroski F-Score Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 6.00 2.00 7.00

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.00 3.00 7.00 7.00

OSTO:SPRINT vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Piotroski F-Score falls into.


OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -7.373 + -8.424 + 113.174 + -12.891 = kr84.5 Mil.
Cash Flow from Operations was -12.182 + -13.887 + 115.843 + -19.291 = kr70.5 Mil.
Revenue was 13.912 + 5.238 + 133.909 + 0 = kr153.1 Mil.
Gross Profit was 8.76 + 3.432 + 132.852 + -1.436 = kr143.6 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(33.836 + 38.601 + 21.438 + 136.661 + 118.972) / 5 = kr69.9016 Mil.
Total Assets at the begining of this year (Mar25) was kr33.8 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.0 Mil.
Total Current Assets was kr115.5 Mil.
Total Current Liabilities was kr12.7 Mil.
Net Income was -5.785 + -5.209 + -4.211 + -5.641 = kr-20.8 Mil.

Revenue was 16.699 + 14.804 + 16.267 + 14.109 = kr61.9 Mil.
Gross Profit was 9.071 + 8.039 + 9.413 + 9.073 = kr35.6 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(52.313 + 48.3 + 46.025 + 42.055 + 33.836) / 5 = kr44.5058 Mil.
Total Assets at the begining of last year (Mar24) was kr52.3 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.0 Mil.
Total Current Assets was kr29.3 Mil.
Total Current Liabilities was kr30.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sprint Bioscience AB's current Net Income (TTM) was 84.5. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sprint Bioscience AB's current Cash Flow from Operations (TTM) was 70.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=84.486/33.836
=2.49692635

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-20.846/52.313
=-0.39848604

Sprint Bioscience AB's return on assets of this year was 2.49692635. Sprint Bioscience AB's return on assets of last year was -0.39848604. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sprint Bioscience AB's current Net Income (TTM) was 84.5. Sprint Bioscience AB's current Cash Flow from Operations (TTM) was 70.5. ==> 70.5 <= 84.5 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/69.9016
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/44.5058
=0

Sprint Bioscience AB's gearing of this year was 0. Sprint Bioscience AB's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=115.45/12.686
=9.10058332

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=29.263/30.206
=0.96878104

Sprint Bioscience AB's current ratio of this year was 9.10058332. Sprint Bioscience AB's current ratio of last year was 0.96878104. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sprint Bioscience AB's number of shares in issue this year was 105.516. Sprint Bioscience AB's number of shares in issue last year was 70.997. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=143.608/153.059
=0.93825257

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=35.596/61.879
=0.5752517

Sprint Bioscience AB's gross margin of this year was 0.93825257. Sprint Bioscience AB's gross margin of last year was 0.5752517. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=153.059/33.836
=4.52355479

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=61.879/52.313
=1.18286086

Sprint Bioscience AB's asset turnover of this year was 4.52355479. Sprint Bioscience AB's asset turnover of last year was 1.18286086. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sprint Bioscience AB has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Piotroski F-Score of 7 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sprint Bioscience AB and its competitors. This is 133% above median its historical median of 3.00. Over the past decade, Sprint Bioscience AB's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Sprint Bioscience AB ranks #41 out of 1336 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Sprint Bioscience AB's Piotroski F-Score too high?
Sprint Bioscience AB's current Piotroski F-Score of 7 is 133% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Sprint Bioscience AB's value of 7 is 133.3% above this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #41 out of 1336 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #41 out of 1336 companies for Piotroski F-Score. This places Sprint Bioscience AB in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Sprint Bioscience AB's value of 7 is 133.3% above this benchmark. Historically, Sprint Bioscience AB's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Sprint Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,336 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Piotroski F-Score is 7, which is 133% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current Piotroski F-Score is 7, which is 133% above median its 10-year median of 3.00 and 133.3% above the Biotechnology industry median of 3.00. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Piotroski F-Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Piotroski F-Score: 7 (133% above median its 10-year median of 3.00)
  • GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
  • GF Score™: 32/100 with 4 warning signs
  • Industry Position: 133.3% above the Biotechnology median (#41 of 1336)

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.06
Price
kr2.18
GF Value